ERBB2 and breast carcinoma: The use of trastuzumab against the human epidermal growth factor receptor 2 (HER2), a protein involved in the development of breast cancer, was found to increase the efficacy of chemotherapy in metastatic breast cancer that overexpresses HER2 [263].